MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
0.3791
+0.0341
+9.88%
After Hours: 0.3521 -0.027 -7.12% 18:15 03/27 EDT
OPEN
0.3863
PREV CLOSE
0.3450
HIGH
0.4000
LOW
0.3456
VOLUME
123.24K
TURNOVER
--
52 WEEK HIGH
1.410
52 WEEK LOW
0.3450
MARKET CAP
2.64M
P/E (TTM)
-0.6758
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting
TipRanks · 3d ago
XORTX Therapeutics held its annual and special meeting of shareholders; 2.4 million shares were represented, about 35% of outstanding shares
Reuters · 3d ago
XORTX Delays Effective Date of One-for-Five Share Consolidation
TipRanks · 3d ago
XORTX Therapeutics Delays 1-for-5 Share Consolidation To April 6, Pending Approvals
Benzinga · 3d ago
XORTX Therapeutics delays 1-for-5 share consolidation effective date to April 6, 2026; consolidation shifts from March 27, 2026
Reuters · 3d ago
XORTX THERAPEUTICS INC - DELAYS SHARE CONSOLIDATION TO APRIL 6, 2026
Reuters · 3d ago
XORTX Announces Results of Annual and Special Meeting of Shareholders
Barchart · 3d ago
More
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Webull offers XORTX Therapeutics Inc stock information, including NASDAQ: XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.